As in vivo tumor trials for ovarian, colon, breast, and prostate cancers became successful, further studies confirmed that tumor blood vessel density was significantly decreased in mice treated with anti-VEGF antibodies [74,76,77,78,79,80]. Here, VEGFA is linked to neoplasm.